Upcoming webinar

Democratizing precision neurology:

Expanding first-line genome access for every child in need

Date: Tuesday, November 17, 2026

Time: 12:00 PM ET | 9:00 AM PT

Webinar duration: 60 minutes

Registrants will receive a recording of the webinar approximately one week after the event.

Learn more about:

In child neurology, defining an underlying genetic etiology is often stalled by fragmented approaches to testing, including tiered, single-gene, or panel testing. A broad “genome-first” model has the potential to simplify clinical workflows by replacing multiple diagnostic steps with a single, highly comprehensive test—helping clinicians reach diagnostic clarity sooner for children with complex neurodevelopmental disorders, refractory epilepsies, or unexplained tone anomalies.

During this session, our speakers will:

Examine the clinical justification for adopting broad genomic sequencing as an initial diagnostic tool
Explore which patient phenotypes may benefit most
Discuss the importance of expanding access to testing to help reduce diagnostic disparities
Demonstrate how a “one-test” strategy can provide clinicians with insights to guide personalized management earlier in a child’s care journey

Natera Honey Pot

Register Now:

First Name*

Last Name*

Email Address*

Job Title*

Phone*

Company Name*

Postal Code*

Country*

I am a*

Do you have any questions for the presenters that you would like to submit before the webinar?

Please fill in the field above only if you have specific questions. Otherwise, leave it blank.

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time.

Hear from our speakers:

Kristina Julich, MD

Chief, Pediatric Neurogenetics Center

UT Austin Pediatric Neurosciences

Dell Children's Medical Center

Brian Schoenfeld, MS, LCGC

Director, Medical Science

Rare Disease, Natera

Zenith™ has been developed and its performance characteristics determined by the CLIA-certified laboratory performing the test. The test has not been cleared or approved by the US Food and Drug Administration (FDA). CAP accredited, ISO 13485 certified, and CLIA certified. © 2026 Natera, Inc. All Rights Reserved.

13011 McCallen Pass, Building A Suite 100 | Austin, TX 78753 | natera.com | Do Not Share My Personal Information | Privacy Policy